Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS

Phase 1 will investigate maximum tolerated dose of OXi4503 as a single agent and in combination with intermediate-dose cytarabine in subjects with relapsed/refractory AML or MDS.
Phase 2 will investigate overall response rate of OXi4503 in combination with intermediate-dose cytarabine in 1) subjects with MDS after failure of 1 prior hypomethylating agent (Arm A) and 2) subjects with relapsed and refractory AML after treatment failure of up to 1 prior chemotherapy regimen (Arm B).

开始日期2015-10-01

申办/合作机构

Oncotelic Therapeutics, Inc.

NCT01085656

/ Terminated临床1期IIT

A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)

This study is intended to determine the safety and maximum tolerated dose of a drug, OXi4503 (combretastatin A1 diphosphate, CA1P, OXiGENE), in patients with relapsed and refractory AML and MDS.

开始日期2011-02-01

申办/合作机构

University of Florida

[+1]

NCT00960557

/ Completed临床1期

A Multicenter, Open-label Phase 1b/2 Study to Assess the Safety and Clinical Activity of Intravenous Combretastatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Primary or Secondary Hepatic Tumor Burden

The purpose of this study is to determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.

开始日期2009-07-01

申办/合作机构

Oncotelic Therapeutics, Inc.

100 项与 Combretastatin A1 Phosphate 相关的临床结果

登录后查看更多信息

100 项与 Combretastatin A1 Phosphate 相关的转化医学

登录后查看更多信息

100 项与 Combretastatin A1 Phosphate 相关的专利（医药）

登录后查看更多信息

129

项与 Combretastatin A1 Phosphate 相关的文献（医药）

2025-01-01·Science of The Total Environment

Biochar application strategies mediating the soil temperature, moisture and salinity during the crop seedling stage in Mollisols

Article

作者: Yan, Pengke ; Wang, Hao ; Wei, Zhimiao ; Niu, Xiaoguang ; Zhang, Haijun ; Aurangzeib, Muhammad ; Tao, Guohui ; Yan, Sihua ; Zhang, Shaoliang

It is well known that biochar remarkably changes the fertility and quality in degraded soils, however, it's still not clear how homogeneous application (HA) and bottom concentrated application of biochar (CA) influences soil moisture (SM), soil temperature (ST) and salts during crops seedling stage. In this study, both HA and CA combining with four levels of 0 (CK), 10 (CA1/HA1), 20 (CA2/HA2) and 40 t ha^-1 (CA3/HA3) were used to reveal how biochar affects SM, ST and soil electrical conductivity (EC) at seedling stage (spring) of maize in moderately degraded Mollisols. The results showed that, the speed of daily ST increase was only significantly slower in CA1 than in CK during the warming stage, performing a "hysteresis effect". Compared with CK, SM and EC were significantly reduced by 32.9 % and 52.9 % in CA3, while increased by 30.4 % and 20.7 % in HA3 during the whole seedling stage. Between the SM/EC and biochar application amount, there was a negative linear relationship in CA, while was a quadratic function relationship in HA during the whole seedling stage. SM (14.49-29.72 %), EC (0.15-0.38 ms cm^-1) and ST (14.86-19.31 °C) were higher in CA1 and HA3 than other treatments in rainfall and drought conditions. DSSA-CERES-maize model adequately simulated the effect of biochar on ST change during maize seedling (nRMSE≤22.6 %, d ≥ 0.59) by integrating initial soil conditions, meteorological data, crop management data, and soil physicochemical properties and crop growth indexes affected by biochar. Generally, HA3 and CA1 was beneficial for improving soil water retention and reducing salt ion leaching, while CA3 accelerated soil drought and increased salt ion leaching during maize seedling stage in Mollisols. The results of this study can provide guidance for the application of crop models in biochar application.

2023-08-01·Tissue and Cell

Liuwei Anxiao San protects gastric mucosa from gastric ulcer in rats by regulating the JAK2/STAT3 pathway

Article

作者: Hou, Mingxing ; Qu, Ze ; Jiang, Dong ; Liu, Yan

Mongolian medicine prescriptions are recognized as promising gastroprotective agents. This study is to explore the effects and mechanisms of Liuwei Anxiao San (LAS) in gastric ulcer (GU). GU rat models were established using acetic acid, followed by treatment with LAS at different doses and/or the JAK2 agonist Coumermycin A1 (CA1). The ulcerous area and inhibition rates were calculated. The mucosal damage and cell apoptosis in gastric tissues were assessed by H&E and TUNEL staining. The activities of SOD, GSH-Px, and CAT, and MDA levels were measured. The levels of pro-inflammatory and anti-inflammatory factors were determined by ELISA. The activation of the JAK2/STAT3 pathway was determined by Western blot. As the results suggested, LAS dose-dependently ameliorated gastric mucosal damage and inhibited oxidative stress and inflammatory response, evidenced by increased activities of SOD, GSH-Px, and CAT, decreased MDA level, increment of anti-inflammatory factors and decrement of pro-inflammatory factors, and inhibited the activation of the JAK2/STAT3 pathway in GU rats. CA1 partly abolished the function of LAS on gastric mucosal injury, oxidative stress, and inflammation in GU rats. In conclusion, LAS protects against gastric mucosal injury in GU rats through inhibition of oxidative stress and inflammation by suppressing the JAK2/STAT3 pathway.

2023-08-01·European journal of oral sciences

Effect of irrigation acid solutions on cleaning and bond strength to post-space dentin.

Article

作者: Alencar, C de Melo ; Barros, A Patricia Oliveira ; Kuga, M Carlos ; Gélio, M Bena ; Zaniboni, J Ferrari ; Besegato, J Felipe ; Belizário, L Garcia ; Godoy, E Maximiliano Fernandez

This study evaluated the effects of irrigating solutions containing 5% boric acid + 1% citric acid or 1% peracetic acid + high concentration hydrogen peroxide on root cleaning and bond strength of cementation systems after 24 h and 6 months of glass fiber post cementation. One hundred and twenty roots were endodontically treated. The specimens were randomized into one of four treatments (n = 10): DW (distilled water); NaOCl_2.5% + EDTA_17% (2.5% sodium hypochlorite solution + 17% EDTA); PA_1% + HP (1% peracetic acid solution + high concentration of hydrogen peroxide); BA_5% + CA_1% (5% boric acid associated with 1% citric acid). The cleaning efficacy in the cervical, middle, and apical thirds of the post-space, and the push-out bond strength at 24 h and 6 months after post cementation were evaluated by Kruskal-Wallis and two-way ANOVA tests, respectively. BA_5% + CA_1% showed statistically significantly superior cleaning efficacy compared to the other solutions. This irrigation protocol also resulted in higher bond strength at 24 h and 6 months, regardless of the root third considered, and this was statistically significantly higher than those seen for DW and PA_1% + HP. For BA_5% + CA_1% irrigation protocol, type 1 adhesive failure was the most prevalent. Post-space irrigation with BA_5% + CA_1% provided both higher cleaning efficacy and better bond strength.

项与 Combretastatin A1 Phosphate 相关的新闻（医药）

2025-02-26

·美迪西Medicilon

Oncotelic与美迪西在核酸药物、纳米制剂等领域达成战略合作

Swipe left for English 2月25日，全球领先的RNA疗法制药企业Oncotelic Therapeutics（OTCQB: OTLC）及其合资公司GMP生物技术有限公司全资子公司Sapu Bioscience, LLC（Oncotelic持有45%股份），与上海美迪西生物医药股份有限公司（股票代码：688202.SH）宣布达成战略合作。此次合作旨在通过美迪西一站式生物医药临床前综合研发服务平台，5年加速推进Oncotelic和SAPU20件新药临床试验申请（IND）项目，目前多个新型抗癌药物IND项目正在积极推进中。 ✦ Oncotelic：全球领先的RNA疗法制药企业 ✦ Oncotelic在肿瘤药物开发领域已深耕37年，专注于RNA疗法与小分子药物的研发创新，尤其在罕见儿科癌症领域取得了丰硕的研究成果。通过合资企业形式，Oncotelic获得多项罕见病疗法认定，包括针对DIPG的OT-101、针对黑色素瘤的CA4P及针对AML的OXi 4503。此后，Oncotelic收购PointR Data Inc.，转型为AI驱动的生物制药公司；获AL-101开发权，计划用于治疗帕金森病、勃起功能障碍等，不断拓展其研发管线与治疗领域。 ✦ 美迪西：全球新药临床前研发服务赋能者 ✦ 美迪西，作为中国少有的一站式生物医药临床前研发服务平台，始终站在国际技术前沿，成功搭建了涵盖ADC、核酸、PROTAC、抗体、多肽、疫苗以及细胞与基因治疗等多个领域的新分子药物研发服务平台。截至2024年底，美迪西已助力约520件IND项目获批临床、60件IND项目实现中美双报获批，积累了丰富的中美欧多国申报的成功经验。聚焦核酸药物、纳米制剂等领域美迪西助力Oncotelic5年推进20个IND项目此次合作不仅是Oncotelic和SAPU在新型癌症疗法领域前瞻战略布局与深度研发信念的深刻体现，也是各方创新愿景高度契合、优势资源深度整合的典范。根据战略协议，美迪西将依托一站式生物医药临床前综合研发服务平台，为Oncotelic和SAPU提供包括药物发现、药学研究（原料药、制剂）、临床前研究（药效、药代、安评）等在内的一站式临床前研发支持，5年助力Oncotelic和SAPU加速推进20个新药项目的IND申报，涵盖核酸药物和纳米制剂等创新药物，为全球新药研发注入崭新的活力与创新动力。 Vuong Trieu 博士 Oncotelic和SAPU董事长&CEO “此次合作将为我们的开发项目带来革命性的变革。美迪西一站式生物医药临床前综合研发服务平台对于加速SAPU和Oncotelic药物研发进程至关重要。我们期待与美迪西继续深化合作，携手推动创新抗癌药物更快进入临床阶段。” 陈春麟博士美迪西创始人、董事长&CEO “非常荣幸能够与Oncotelic和SAPU达成战略合作。我们将依托在新药研发领域所积累的研发技术和国际经验，为Oncotelic和SAPU提供一站式临床前研发服务，携手并进，共同加速新药研发的进程，为全球病患开辟新的治疗选择。” 关于Oncotelic Oncotelic Therapeutics（前身为Mateon Therapeutics, Inc.）最初于1988年在纽约州成立，名为OXiGENE, Inc.，1992年重新在特拉华州注册，2016年更名为Mateon Therapeutics, Inc.，并于2020年11月更名为Oncotelic Therapeutics, Inc.。公司致力于利用其在肿瘤药物开发领域的深厚专长，以改善癌症患者（尤其是罕见儿科癌症）的治疗效果和生存率。通过旗下持有45%股权的合资企业GMP Biotechnology Limited，Oncotelic已获得多项罕见儿科疾病认定：针对弥漫性内生型桥脑胶质瘤（DIPG）的OT-101疗法、针对黑色素瘤的CA4P疗法，以及针对急性髓系白血病（AML）的OXi 4503疗法。2019年11月，Oncotelic收购了PointR Data Inc.，旨在打造一家由人工智能驱动的生物科技公司。此外，公司于2021年第四季度获得了AL-101（用于鼻内递送阿扑吗啡）的开发权，计划将其应用于帕金森病、勃起功能障碍、女性性功能障碍及性欲减退症的治疗。这些疾病均影响着庞大患者群体，存在迫切的临床需求。有关AL-101的详细信息，请参阅公司于2024年4月12日向美国证券交易委员会（SEC）提交的2023年度10-K表格报告。关于美迪西美迪西（股票代码：688202.SH）成立于2004年，总部位于上海，致力于为全球制药企业、研究机构及科研工作者提供全方位的临床前新药研究服务。美迪西的一站式综合服务以强有力的项目管理和更高效、高性价比的研发服务助力客户加速新药研发进程，服务涵盖医药临床前新药研究的全过程，包括药物发现、药学研究及临床前研究。至2024年底，美迪西已为全球超2000家客户提供药物研发服务，参与研发完成的新药及仿制药项目已有约520件IND获批临床，与国内外优质客户共同成长。美迪西将继续立足全球视野，聚力中国创新，为人类健康贡献力量！右滑查看中文版 AGOURA HILLS, Calif., February 25, 2025– Oncotelic Therapeutics, Inc. (OTCQB:OTLC). Oncotelic Therapeutics Inc., a leader in RNA-based therapeutics, including its subsidiaries (“Oncotelic”) and including Sapu Bioscience, LLC (“SAPU”), a wholly owned subsidiary of GMP Biotechnology Limited in which Oncotelic is a 45% owner, is pleased to announce a strategic partnership with Shanghai Medicilon Inc. (“Medicilon”) (stock code: 688202.SH). Through this collaboration, Oncotelic and SAPU will utilize Medicilon’s industry-leading rapid IND development platform to support up to 20 Investigational New Drug (IND) projects. Six of these INDs are ongoing and are focused on next-generation anticancer agents. Oncotelic and SAPU's partnership with Medicilon is poised to significantly accelerate the development of our innovative oncology pipeline. This collaboration reflects our strategic move to strengthen our position as a leader in novel cancer therapies. Enabling Rapid Growth: Medicilon’s integrated platform for drug discovery, pharmaceutical research, and preclinical development will expedite the regulatory pathways for Oncotelic’s and SAPU’s upcoming IND submissions. Portfolio Expansion: This initiative will initially focus on the current six INDs but has the potential to extend up to 20 projects, reflecting the depth of Oncotelic’s and its affiliates’ R&D programs. Dr. Vuong Trieu Chairman and CEO of Oncotelic and SAPU “This partnership is poised to be a game-changer for our development programs. The ability to access a rapid IND-enabling platform is crucial for accelerating SAPU’s and Oncotelic’s development programs. We look forward to continued success working with Medicilon as we advance innovative anticancer agents to the clinic.” Dr. Chen Chunlin Chairman,Founder and CEO of Medicilon “We are excited to partner with Oncotelic and SAPU and contribute our international experience in drug R&D. We are a comprehensive, one-stop services organization, from early discovery to IND registration, built to accelerate the translation of Oncotelic and SAPU’s pipeline into new therapeutic options for patients.” About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (“AML” through OXi 4503). Oncotelic also acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our 2023 Annual Report on form 10-K filed with the SEC on April 12, 2024. About Medicilon From its inception in 2004, Shanghai Medicilon Inc. (stock code: 688202.SH) has been committed to providing comprehensive R&D services to pharmaceutical companies, research institutions, and any organizations working in the preclinical space. By the end of 2024, Medicilon has provided drug development services to over 2,000 clients worldwide, and has been involved in the research and development of 520 new drugs and generic drug projects that have been approved for clinical trials with IND applications.

抗体药物偶联物临床申请并购核酸药物

2025-02-21

·今日头条

晚期实体瘤治疗新突破：中山大学1期研究揭示口服血管破坏剂的潜力

点击蓝字关注我们【导读】 DX1002是一种口服血管破坏剂，在临床前研究中显示出有希望的结果，导致各种动物模型中的肿瘤脉管系统破坏和异种移植肿瘤坏死。 2025年2月18日，中山大学肿瘤防治中心的研究团队在期刊《Cell Reports Medicine》上合作发表了题为“First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors”的研究论文。研究结果表明， DX1002在晚期实体瘤患者中表现出良好的安全性和早期抗肿瘤活性，具有独特的肿瘤血管靶向性，且与化疗联合治疗显示出潜在协同效应，值得进一步临床研究。 https://www-cell-com.libproxy1.nus.edu.sg/cell-reports-medicine/fulltext/S2666-3791(25)00042-4 01 研究背景在1990年代，血管靶向疗法（VTT）的使用已被确立为一种可行性，VTT有两种主要类型，即血管破坏剂（VDA）和血管生成抑制剂（AIA）。AIAs可以抑制肿瘤血管的形成，而VDAs可以导致现有肿瘤血管的快速和选择性闭合，并导致缺血和广泛出血性坏死。先前的早期临床试验表明，VDA具有可控的安全性和初步的抗肿瘤疗效。VDA包括两个主要类别，即单克隆抗体（如Tarvacin）和小分子VDA。小分子VDA可以根据其分子结构进一步分为秋水仙碱、CA4类似物（如CA4P、ombrabulin、ZD6126、OXi4503、BNC105P、DX1002和C118P）和类黄酮药物（例如DMXAA和MN029）。在动物模型中，这些药物已显示出有希望的抗肿瘤作用。其中一些，包括CA4P、ombrabulin和DMXAA （ASA404），已进入3期试验。然而，其他研究的进展受到阻碍，许多研究仍处于早期临床阶段或已被终止。因此，尽管具有潜力，但尚未有VDA获得抗肿瘤治疗的批准。CA4P是最具代表性的VDA之一，但CA4P的缺陷如分子结构不稳定、靶向作用对肿瘤血管的选择性差，以及对心血管系统和周围神经的毒性等极大地限制了其应用。图形摘要 02 抗肿瘤功效所有17例入组患者均可评估抗肿瘤反应。其中12例患者达到SD，其余5例患者主要对DX1002耐药，总体疾病控制率（DCR）为70.6%。未观察到完全或部分反应；因此，客观缓解率为0%，中位进展时间（TTP）为2.70个月。600mg组中的1例NSCLC患者（患者10）达到SD并持续6.5个月，直到撤回知情同意书并停止治疗。该患者的目标病灶总和仅增加了4.1%。此外，团队选择了1名患者（患者01），其肿瘤病灶适合用对比增强超声（CEUS）观察，并记录了血供的变化。该患者实现了4.5个月的TTP，据观察，随着DX1002给药而出现空腔和坏死，而血液供应显著减少。 CEUS观察到的DX1002药物治疗后，典型肿瘤病灶的血供变化。 03 总结 1. DX1002的安全性和耐受性：在首次人体1期临床试验中，DX1002在50-600mg剂量范围内每日1次给药是安全且耐受性良好的，最大耐受剂量（MTD）为600mg。未观察到剂量限制性毒性（DLT），且与其他血管破坏剂（VDA）相比，DX1002未引起心脏和周围神经毒性，显示出更好的安全性。 2. DX1002的抗肿瘤活性：尽管未观察到完全缓解（CR）或部分缓解（PR），但12例患者达到疾病稳定（SD），总体疾病控制率（DCR）为70.6%。DX1002在临床前研究中显示出破坏肿瘤血管并导致肿瘤组织坏死的能力，但肿瘤周围残留的活细胞可能限制了其作为单一疗法的抗肿瘤活性。 3. DX1002的独特机制： DX1002通过在CA4二苯乙烯结构的双键位置引入羧基，增强了稳定性，并显示出对肿瘤血管的选择性破坏，而不伤害正常血管，表明其具有更好的安全性和靶向性。 4. 联合治疗的潜力：临床前研究表明，DX1002与化疗联合使用可增强抗肿瘤效果。3例患者在DX1002治疗后接受后续治疗（如化疗）表现出部分缓解（PR），提示DX1002可能使肿瘤对化疗重新敏感，支持其在联合治疗中的进一步研究。 5. 未来研究方向：基于1期试验的结果，DX1002的推荐2期剂量（RP2D）为每日1次600mg，连续21天给药。2期临床试验（CTR20200996）已启动，进一步评估DX1002单药及与化疗联合治疗的疗效和安全性。参考资料： 1.Pettit, G.R. ∙ Singh, S.B. ∙ Hamel, E. ... Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 Experientia. 1989; 45:209-211 2.Pettit, G.R. ∙ Singh, S.B. ∙ Boyd, M.R. ... Antineoplastic Agents. 291. Isolation and Synthesis of Combretastatins A-4, A-5, and A-6 J. Med. Chem. 1995; 38:1666-1672 [Erratum to document cited in CA122:290568] 【关于投稿】转化医学网（360zhyx.com）是转化医学核心门户，旨在推动基础研究、临床诊疗和产业的发展，核心内容涵盖组学、检验、免疫、肿瘤、心血管、糖尿病等。如您有最新的研究内容发表，欢迎联系我们进行免费报道（公众号菜单栏-在线客服联系），我们的理念：内容创造价值，转化铸就未来！转化医学网（360zhyx.com）发布的文章旨在介绍前沿医学研究进展，不能作为治疗方案使用；如需获得健康指导，请至正规医院就诊。热门推荐活动点击免费报名 🕓 全国｜2024年12月-2025年03月 ▶ 中国转化医学产业大会 🕓 上海｜2025年02月28日-03月01日 ▶ 第四届长三角单细胞组学技术应用论坛暨空间组学前沿论坛点击对应文字查看详情

临床3期临床1期临床结果

2024-11-06

·GlobeNewswire-Health Care

ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024

AGOURA HILLS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at SITC 2024. Dr. Cynthia Lee, VP of R&D will be presenting Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to: https://www.sitcancer.org/home. Dr. Lee has been leading our R&D programs for the past several years including the buildout of our GMP facility in San Diego. The presentations are: Abstract Number 198: TGFB2 mRNA levels prognostically interact with Interferon-alpha receptor activation of IRF9 and IFI27, and makers for tumor-associated macrophages impacting overall survival in PDAC. Authors Sanjive Qazi, Cynthia Lee, Vuong Trieu Abstract Number 218: Evaluating the prognostic impact of Transforming growth factor beta 2 mRNA levels, in conjunction with Interferon-gamma receptor activation of IRF5 and expression of CD276/B7-H3 in low-grade gliomas. Authors Sanjive Qazi, Anthony Maida, Vuong Trieu Abstract Number 1444: Meta-analysis comparing the incidence of serious adverse events, overall survival, and progression-free survival in PDAC patients harboring unresectable tumors treated with mFOLFIRINOX or FOLFIRINOX. Authors Vuong Trieu, Sanjive Qazi, Seymour Fein, Anthony Maida, Tenshang Joh About Oncotelic Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. Oncotelic’s first in class TGFB2 therapeutic to treat pancreatic cancer and glioblastoma is being developed through its JV – Sapu Bio. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

并购信使RNA

100 项与 Combretastatin A1 Phosphate 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05143

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝细胞癌	临床2期	-	Oncotelic Therapeutics, Inc.	-
急性髓性白血病	临床申请批准	美国	Oncotelic Therapeutics, Inc.	2015-10-01
骨髓增生异常综合征	临床申请批准	美国	Oncotelic Therapeutics, Inc.	2015-10-01
复发性急性髓细胞白血病	临床申请批准	美国	Oncotelic Therapeutics, Inc.	2015-10-01
恶性腹水	临床申请批准	澳大利亚	Oncotelic Therapeutics, Inc.	2013-05-09
肝癌	临床申请批准	澳大利亚	Oncotelic Therapeutics, Inc.	2013-04-02
肿瘤转移	临床申请批准	澳大利亚	Oncotelic Therapeutics, Inc.	2009-07-01
晚期恶性实体瘤	临床申请批准	英国	Oncotelic Therapeutics, Inc.	2005-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02576301 (GlobeNewswire) 人工标引	临床1期	急性髓性白血病	26	Combretastatin A1 Phosphate+cytarabine	(簾窪夢鬱鑰廠艱製簾鏇) = 獵鹽繭廠夢壓鑰遞範鹹壓醖鹽鹹鏇鑰醖網簾夢 (廠齋鏇築鹽膚醖築鬱繭 ) 更多	积极	2019-12-27
NCT00977210 (Pubmed \| Cancers (Basel)) 人工标引	临床1期	急性髓性白血病	29	OXi4503	(憲製夢積獵蓋壓襯蓋淵) = 9.76 mg/m2 ombination with 1 g/m2 ARA-C 淵積醖膚壓衊衊衊夢構 (蓋積鑰範獵醖鏇鏇壓築 ) 更多	积极	2019-12-26
NCT02576301 (GlobeNewswire) 人工标引	临床1/2期	急性髓性白血病	26	Cytarabine+Combretastatin A1	(網膚餘憲顧糧顧鹹鹽鏇) = 簾築衊簾願觸夢壓鹽糧夢繭積膚膚鹹鏇衊鬱鑰 (鹹簾網積艱艱願鹽選選 ) 更多	积极	2019-12-23
AHNS2012	N/A	头颈部肿瘤	-	Oxi4503	齋衊鹽醖獵網襯蓋鏇膚(鹹觸襯觸窪鹽鹽衊窪鹽) = extensive areas of necrosis and hemorrhaging compared to untreated controls 網鏇願鬱鹽膚願獵衊獵 (壓餘簾築醖壓鑰選淵膚 ) 更多	-	2012-07-24
AHNS2012	N/A	头颈部肿瘤	-	OXI4503 (Untreated controls)		-	2012-07-24
ASCO2007	临床1期	晚期恶性实体瘤	11	OXi4503	築膚範願淵餘鹽蓋觸夢(積獵顧廠積範艱願夢廠) = showed significant reduction in Ktrans in one patient (0.24mg/m^2) 觸顧簾願糧觸淵選艱憲 (鏇淵壓鏇鑰築窪衊築積 ) 更多	-	2007-06-20